338 related articles for article (PubMed ID: 25426117)
1. Erythropoietin and cancer: the unintended consequences of anemia correction.
Debeljak N; Solár P; Sytkowski AJ
Front Immunol; 2014; 5():563. PubMed ID: 25426117
[TBL] [Abstract][Full Text] [Related]
2. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
3. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
4. The erythropoietin receptor in normal and cancer tissues.
Jelkmann W; Bohlius J; Hallek M; Sytkowski AJ
Crit Rev Oncol Hematol; 2008 Jul; 67(1):39-61. PubMed ID: 18434185
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin biology in cancer.
Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and Its Angiogenic Activity.
Kimáková P; Solár P; Solárová Z; Komel R; Debeljak N
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703764
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and the vascular wall: the controversy continues.
Jelkmann W; Elliott S
Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S37-43. PubMed ID: 22682530
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin in cancer: the new face of an old friend.
Megalakaki C
J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
[TBL] [Abstract][Full Text] [Related]
9. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
10. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study.
Trincavelli ML; Da Pozzo E; Ciampi O; Cuboni S; Daniele S; Abbracchio MP; Martini C
Int J Mol Sci; 2013 Jan; 14(2):2258-81. PubMed ID: 23348925
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative.
Chamorro ME; Wenker SD; Vota DM; Vittori DC; Nesse AB
Biochim Biophys Acta; 2013 Aug; 1833(8):1960-8. PubMed ID: 23602701
[TBL] [Abstract][Full Text] [Related]
13. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study.
Maggioni D; Nicolini G; Chiorazzi A; Meregalli C; Cavaletti G; Tredici G
J Neurosci Res; 2010 Nov; 88(14):3171-9. PubMed ID: 20722073
[TBL] [Abstract][Full Text] [Related]
14. Alternative Erythropoietin Receptors in the Nervous System.
Ostrowski D; Heinrich R
J Clin Med; 2018 Feb; 7(2):. PubMed ID: 29393890
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin, erythropoiesis and beyond.
Chateauvieux S; Grigorakaki C; Morceau F; Dicato M; Diederich M
Biochem Pharmacol; 2011 Nov; 82(10):1291-303. PubMed ID: 21782802
[TBL] [Abstract][Full Text] [Related]
16. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story?
Calò LA; Davis PA; Piccoli A; Pessina AC
Nephron Physiol; 2006; 103(3):p107-11. PubMed ID: 16554668
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
18. The effect of erythropoietin on normal and neoplastic cells.
Elliott S; Sinclair AM
Biologics; 2012; 6():163-89. PubMed ID: 22848149
[TBL] [Abstract][Full Text] [Related]
19. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
[TBL] [Abstract][Full Text] [Related]
20. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
